EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies

Shuichi Ito iD, Yo Morita, Makoto Nitami, Ryutaro Iwama, Akihiro Nakajima, Hisashi Yamanaka, Masataka Honda

Modern Rheumatology · 2024

DOI: 10.1093/mr/roae056 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Shuichi Ito und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan. Hauptthemen laut MEDLINE: Febuxostat, Hyperuricemia, Gout Suppressants, Gout. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Urate-lowering efficacy and safety of febuxostat was evaluated in paediatric patients with hyperuricaemia including gout.

Methods

A Phase 2 study of febuxostat in paediatric patients aged 6–18 years with hyperuricaemia including gout was conducted. We evaluated the proportion of patients achieving serum uric acid (sUA) level ≤6.0 mg/dl at Week 26, and long-term safety and efficacy at Week 52. We also considered efficacy stratified by renal function.

Results

Thirty patients (10 at <40 kg and 20 at ≥40 kg) were enrolled. Twenty-four were males, 29 had asymptomatic hyperuricaemia, and 1 had gout. Age was 8 to 18 years. Of these, 63.3% (95% confidence interval 43.9–80.1%) achieved a sUA level of ≤6.0 mg/dl at Week 26. sUA level (mean ± standard deviation) was 5.55 ± 0.87 mg/dl, reduced from 9.01 ± 1.23 mg/dl at baseline. Febuxostat efficacy appeared similar for mild to moderate renal dysfunction and with normal renal function. There were no major safety issues.

Conclusions

In paediatric patients with hyperuricaemia including gout, febuxostat showed long-term, well-controlled urate-lowering efficacy with no major safety issues. Findings suggest that no dose adjustment is required for paediatric patients with mild to moderate renal dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FebuxostatHyperuricemiaGout SuppressantsGoutUric AcidHumansChildMaleAdolescentFemaleTreatment OutcomeJapanEast Asian People

Stichwörter der Autor:innen

Febuxostatpaediatric goutpaediatric hyperuricaemiarenal dysfunctionurate-lowering therapy

Substanzen

FebuxostatGout SuppressantsUric Acid

Autor:innen und Institutionen

  • Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan.
  • Clinical Development Department, Teijin Pharma Limited, Tokyo, Japan.
  • Toxicology & DMPK Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited, Tokyo, Japan.
  • Clinical Development Control Department, Teijin Pharma Limited, Tokyo, Japan.
  • Rheumatology, Sanno Medical Center, Tokyo, Japan.
  • Department of Rheumatology, International University of Health and Welfare, Chiba, Japan.

ORCID-Profile: Shuichi Ito

Zitieren

APA

Ito, S., Morita, Y., Nitami, M., Iwama, R., Nakajima, A., Yamanaka, H., & Honda, M. (2024). Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies. Modern Rheumatology. https://doi.org/10.1093/mr/roae056

Vancouver

Ito S, Morita Y, Nitami M, Iwama R, Nakajima A, Yamanaka H, et al. Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies. Modern Rheumatology. 2024. doi:10.1093/mr/roae056

BibTeX
@article{Ito2024,
  author = {Ito, Shuichi and Morita, Yo and Nitami, Makoto and Iwama, Ryutaro and Nakajima, Akihiro and Yamanaka, Hisashi and Honda, Masataka},
  title = {Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roae056}
}
Kostenlos starten →